TY  - JOUR
T1  - Systemic inflammatory response syndrome and magic bullets: Finding the target and improving the aim
AU  - Gosling P, Bascom JU, Zikria BA
Y1  - 1998/03/01
N1  - 
JO  - Archives of Surgery
SP  - 334
EP  - 334
VL  - 133
IS  - 3
N2  - 
He correctly points out the shortcomings of trials of powerful modulators of inflammation in patients with a wide variety of diseases and disease severity, and recommends more critical patient selection for inclusion in therapeutic trials. This includes "rapidly identifying circulating endotoxin (by a lipopolysaccharide assay), Gram-negative bacteremia (by rapid culture techniques), and . . . elevated mediator levels, such as interleukin 6 or TNF [tumor necrosis factor]. . . ." However, because individual mediator levels change rapidly and have overlapping functions, even if rapid bedside patient measurement were possible, it may not identify those patients at risk of SIRS.

SN  - 0004-0010
M3  - doi: 
UR  - http://dx.doi.org/
ER  -